{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:16Z","timestamp":1791994576492,"version":"4.4.0"},"reference-count":139,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jaad.2020.05.161","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T21:17:28Z","timestamp":1614979048000},"page":"18-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Subepithelial autoimmune bullous dermatoses disease activity assessment and therapy"],"prefix":"10.1016","volume":"85","author":[{"given":"Carmen M.","family":"Montagnon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia S.","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedee F.","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Camilleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislav N.","family":"Tolkachjov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2020.05.161_bib1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2020.05.161_bib2","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1038\/jid.2009.72","article-title":"Reliability and convergent validity of two outcome instruments for pemphigus","volume":"129","author":"Rosenbach","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.05.161_bib3","doi-asserted-by":"crossref","first-page":"854795","DOI":"10.1155\/2012\/854795","article-title":"Association of autoantibodies to BP180 with disease activity in Greek patients with bullous pemphigoid","volume":"2012","author":"Patsatsi","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.161_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2340\/00015555-2473","article-title":"The reliability, validity and responsiveness of two disease scores (BPDAI and ABSIS) for bullous pemphigoid: which one to use?","volume":"97","author":"Wijayanti","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"10.1016\/j.jaad.2020.05.161_bib5","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jamadermatol.2013.4972","article-title":"Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire","volume":"149","author":"Sebaratnam","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.05.161_bib6","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/bjd.12623","article-title":"The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease","volume":"169","author":"Tjokrowidjaja","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.05.161_bib7","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1046\/j.1523-1747.2002.19529.x","article-title":"Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the\u00a0BP180 ectodomain","volume":"119","author":"Hofmann","year":"2002","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.161_bib8","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archderm.136.2.174","article-title":"Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid","volume":"136","author":"Schmidt","year":"2000","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.161_bib9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clim.2008.04.012","article-title":"Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid","volume":"128","author":"Di Zenzo","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaad.2020.05.161_bib10","article-title":"Anti-BP180 and anti-BP230 enzyme-linked immunosorbent assays for diagnosis and disease activity tracking of bullous pemphigoid: a prospective cohort study","author":"Chanprapaph","year":"2019","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"7","key":"10.1016\/j.jaad.2020.05.161_bib11","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1111\/jdv.16363","article-title":"Anti-BP180 autoantibody levels at diagnosis correlate with 1-year mortality rates in patients with bullous pemphigoid","volume":"34","author":"Monshi","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.161_bib12","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jaad.2019.03.062","article-title":"Circulating bullous pemphigoid autoantibodies in the setting of negative direct immunofluorescence findings for bullous pemphigoid: a single-center retrospective review","volume":"81","author":"Wang","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2020.05.161_bib13","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1038\/jid.2014.263","article-title":"Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid","volume":"134","author":"Le Jan","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.161_bib14","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2020.05.161_bib15","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/jid.2008.412","article-title":"A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study","volume":"129","author":"Joly","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.05.161_bib16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.161_bib17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000324899","article-title":"Management of bullous pemphigoid with topical steroids in the clinical practice of a single center: outcome at 6 and 12 months","volume":"222","author":"Ingen-Housz-Oro","year":"2011","journal-title":"Dermatology"},{"issue":"10079","key":"10.1016\/j.jaad.2020.05.161_bib18","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib19","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.jaad.2010.09.718","article-title":"Nonbullous pemphigoid treated with doxycycline monotherapy: report of 4 cases","volume":"64","author":"Safa","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2020.05.161_bib20","first-page":"327","article-title":"Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore","volume":"41","author":"Goon","year":"2000","journal-title":"Singapore Med J"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.161_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2133.1989.tb07769.x","article-title":"Dapsone as first line therapy for bullous pemphigoid","volume":"120","author":"Venning","year":"1989","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.05.161_bib22","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1001\/archderm.1977.01640050070009","article-title":"Bullous pemphigoid responding to sulfapyridine and the sulfones","volume":"113","author":"Person","year":"1977","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.161_bib23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0190-9622(96)80085-5","article-title":"Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases","volume":"34","author":"Bouscarat","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.05.161_bib24","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/bjd.15649","article-title":"An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone","volume":"177","author":"Sticherling","year":"2017","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.161_bib25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.aller.2010.12.009","article-title":"Efficacy and safety of azathioprine and dapsone as an adjuvant in the treatment of bullous pemphigoid","volume":"40","author":"Tirado-Sanchez","year":"2012","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"7","key":"10.1016\/j.jaad.2020.05.161_bib26","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/archderm.144.7.946-a","article-title":"Comparative effectiveness of azathioprine or mycophenolate mofetil as an adjuvant for the treatment of bullous pemphigoid","volume":"144","author":"Bystryn","year":"2008","journal-title":"Arch Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2020.05.161_bib27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00002512-200825080-00001","article-title":"Role of methotrexate in the treatment of bullous pemphigoid in the elderly","volume":"25","author":"Patton","year":"2008","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jaad.2020.05.161_bib28","article-title":"Dapsone advantages over trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis in immunobullous patients","author":"Siscos","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.161_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archderm.1993.01680220061016","article-title":"Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid","volume":"129","author":"Guillaume","year":"1993","journal-title":"Arch Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2020.05.161_bib30","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/archderm.143.12.1536","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid","volume":"143","author":"Beissert","year":"2007","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.161_bib31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1684\/ejd.2012.1717","article-title":"High-dose intravenous immunoglobulin in the treatment of adult patients with bullous pemphigoid","volume":"22","author":"Gaitanis","year":"2012","journal-title":"Eur J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib32","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1365-2133.2011.10531.x","article-title":"Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study","volume":"165","author":"Du-Thanh","year":"2011","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.161_bib33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","article-title":"A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid","volume":"85","author":"Amagai","year":"2017","journal-title":"J Dermatol Sci"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1067\/mjd.2001.116337","article-title":"Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment","volume":"45","author":"Ahmed","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.05.161_bib35","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jaad.2019.11.023","article-title":"Clinical outcome and safety of rituximab therapy for pemphigoid diseases","volume":"82","author":"Tovanabutra","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.05.161_bib36","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.161_bib37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaad.2019.03.049","article-title":"Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients","volume":"81","author":"Polansky","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.161_bib38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and omalizumab for the treatment of bullousp emphigoid: a systematic review of the literature","volume":"20","author":"Kremer","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2020.05.161_bib39","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"9","author":"Lamberts","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.161_bib40","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000339071","article-title":"Adjuvant treatment of recalcitrant bullous pemphigoid with immunoadsorption","volume":"224","author":"Muller","year":"2012","journal-title":"Dermatology"},{"issue":"9","key":"10.1016\/j.jaad.2020.05.161_bib41","first-page":"1109","article-title":"Adjuvant treatment of severe\/refractory bullous pemphigoid with protein A immunoadsorption","volume":"16","author":"Hubner","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.161_bib42","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1046\/j.1365-4362.2000.00876.x","article-title":"Plasmapheresis as a steroid saving procedure in bullous pemphigoid","volume":"39","author":"Egan","year":"2000","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.161_bib43","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/1744-9987.12536","article-title":"Bullous pemphigoid successfully treated with a combination therapy of plasmapheresis followed by intravenous high dose immunoglobulin","volume":"21","author":"Hattori","year":"2017","journal-title":"Ther Apher Dial"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib44","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/jdv.12155","article-title":"Treatment of bullous pemphigoid with low-dose oral cyclophosphamide: a case series of 20 patients","volume":"28","author":"Gual","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.jaad.2020.05.161_bib45","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1346-8138.2004.tb00571.x","article-title":"A\u00a0case of refractory bullous pemphigoid with plasmapheresis-associated thrombopenia: efficacy of pulsed intravenous cyclophosphamide therapy","volume":"31","author":"Ogawa","year":"2004","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.05.161_bib46","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1046\/j.1365-2133.1996.131866.x","article-title":"Successful treatment of bullous pemphigoid with pulsed intravenous cyclophosphamide","volume":"134","author":"Itoh","year":"1996","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.161_bib47","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/ijd.14270","article-title":"Tetracycline, nicotinamide, and lesionally administered clobetasol as a therapeutic option to prednisone in patients with bullous pemphigoid: a comparative, retrospective analysis of 106 patients with long-term follow-up","volume":"58","author":"Kalinska-Bienias","year":"2019","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.161_bib48","first-page":"205","article-title":"Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases","volume":"76","author":"Schmidt","year":"2005","journal-title":"Cutis"},{"issue":"5","key":"10.1016\/j.jaad.2020.05.161_bib49","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1001\/archderm.144.5.658","article-title":"Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies","volume":"144","author":"Czernik","year":"2008","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.161_bib50","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.161_bib51","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaad.2015.11.030","article-title":"Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: a retrospective study with a 6-year follow-up","volume":"74","author":"Ahmed","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.161_bib52","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/jamadermatol.2018.5049","article-title":"Assessment of the prevalence of mucosal involvement in bullous pemphigoid","volume":"155","author":"Kridin","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.161_bib53","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/bjd.16553","article-title":"Prospective study in bullous pemphigoid: association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score","volume":"179","author":"Holtsche","year":"2018","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.161_bib54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijwd.2019.02.001","article-title":"Successful management of bullous pemphigoid with dimethyl fumarate therapy: a case report","volume":"5","author":"Bilgic-Temel","year":"2019","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.jaad.2020.05.161_bib55","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fimmu.2019.00978","article-title":"Current clinical trials in pemphigus and pemphigoid","volume":"10","author":"Izumi","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2020.05.161_bib56","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jid.2019.03.116","article-title":"040 Th\/Tc9 and Th\/Tc17 pathways are augmented in moderate-to-extensive bullous pemphigoid patients and suppressed by Bertilimumab","volume":"139","author":"Kameyama","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2020.05.161_bib57","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2020.05.161_bib58","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.jid.2019.04.025","article-title":"Specific inhibition of the classical complement pathway prevents C3 deposition along the dermal-epidermal junction in\u00a0bullous pemphigoid","volume":"139","author":"Freire","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.161_bib59","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.161_bib60","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2014.08.024","article-title":"Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts","volume":"72","author":"Murrell","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib61","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1111\/ijd.14765","article-title":"Custom dental trays with topical corticosteroids for management of gingival lesions of mucous membrane pemphigoid","volume":"59","author":"Kulkarni","year":"2020","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib62","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1067\/moe.2003.139","article-title":"Treatment of severe erosive gingival lesions by topical application of clobetasol propionate in custom trays","volume":"95","author":"Gonzalez-Moles","year":"2003","journal-title":"Oral Surg Oral\u00a0Med Oral Pathol Oral Radiol Endod"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib63","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/ced.14188","article-title":"Management of mucous membrane pemphigoid in a joint oral medicine-dermatology clinic","volume":"45","author":"Finn","year":"2020","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.161_bib64","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1754-4505.2006.tb01512.x","article-title":"Successful treatment of mucous membrane pemphigoid with tacrolimus","volume":"26","author":"Suresh","year":"2006","journal-title":"Spec Care Dentist"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.161_bib65","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0030-4220(93)90012-S","article-title":"Clinical, historic, and therapeutic features of cicatricial pemphigoid. A literature review and open therapeutic trial with corticosteroids","volume":"76","author":"Vincent","year":"1993","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.161_bib66","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1111\/jdv.13894","article-title":"Localized oral mucous membrane pemphigoid: successful topical treatment with 1% tacrolimus solution as steroid-sparing therapy","volume":"31","author":"Al-Shehhi","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib67","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1046\/j.1365-2230.1998.00379.x","article-title":"Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy","volume":"23","author":"Reiche","year":"1998","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib68","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1600-0714.2008.00653.x","article-title":"The management of oral mucous membrane pemphigoid with dapsone and topical corticosteroid","volume":"37","author":"Arash","year":"2008","journal-title":"J Oral Pathol Med"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.161_bib69","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1079-2104(99)70110-1","article-title":"A retrospective study of the management of oral mucous membrane pemphigoid with dapsone","volume":"88","author":"Ciarrocca","year":"1999","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib70","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.76.6.332","article-title":"Dapsone therapy for the acute inflammatory phase of ocular pemphigoid","volume":"76","author":"Fern","year":"1992","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.161_bib71","first-page":"201","article-title":"Dapsone therapy of cicatricial pemphigoid","volume":"7","author":"Rogers","year":"1988","journal-title":"Semin Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.161_bib72","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0190-9622(82)70014-3","article-title":"Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone","volume":"6","author":"Rogers","year":"1982","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib73","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/bjo.80.6.549","article-title":"Sulphapyridine\u2014a new agent for the treatment of ocular cicatricial pemphigoid","volume":"80","author":"Elder","year":"1996","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"10.1016\/j.jaad.2020.05.161_bib74","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archdermatol.2011.54","article-title":"Rituximab for patients with refractory mucous membrane pemphigoid","volume":"147","author":"Le Roux-Villet","year":"2011","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib75","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00417-017-3603-3","article-title":"Rituximab in the treatment of ocular cicatricial pemphigoid: a retrospective cohort study","volume":"255","author":"You","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.jaad.2020.05.161_bib76","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jaad.2016.01.020","article-title":"Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP)","volume":"74","author":"Maley","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.05.161_bib77","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report","volume":"117","author":"Foster","year":"2010","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.jaad.2020.05.161_bib78","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1097\/ICO.0000000000001024","article-title":"Combined use of rituximab and intravenous immunoglobulin for severe autoimmune cicatricial conjunctivitis- an interventional case series","volume":"35","author":"Steger","year":"2016","journal-title":"Cornea"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib79","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/ICO.0b013e31826af7b8","article-title":"Treatment of mucous membrane pemphigoid with mycophenolate mofetil","volume":"32","author":"Nottage","year":"2013","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.161_bib80","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.oooo.2012.01.030","article-title":"Treatment of mucous membrane pemphigoid with the combination of mycophenolate mofetil, dapsone, and prednisolone: a case series","volume":"114","author":"Staines","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.161_bib81","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ajo.2009.05.008","article-title":"Azathioprine for ocular inflammatory diseases","volume":"148","author":"Pasadhika","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.161_bib82","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0002-9394(14)77908-5","article-title":"Immunosuppressive therapy in ocular cicatricial pemphigoid","volume":"96","author":"Mondino","year":"1983","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jaad.2020.05.161_bib83","doi-asserted-by":"crossref","first-page":"8372146","DOI":"10.1155\/2018\/8372146","article-title":"Long-term follow-up after intravenous immunoglobulin therapy in patients with severe ocular mucous membrane pemphigoid unresponsive to conventional therapy","volume":"2018","author":"Leuci","year":"2018","journal-title":"J Ophthalmol"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.161_bib84","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1080\/09273948.2018.1433302","article-title":"Management of ocular cicatricial pemphigoid with intravenous immunoglobulin monotherapy","volume":"27","author":"Ma","year":"2019","journal-title":"Ocul Immunol Inflam"},{"issue":"7","key":"10.1016\/j.jaad.2020.05.161_bib85","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.ophtha.2003.11.012","article-title":"Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up","volume":"111","author":"Sami","year":"2004","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.jaad.2020.05.161_bib86","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/S0161-6420(99)90496-7","article-title":"Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study","volume":"106","author":"Foster","year":"1999","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.161_bib87","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clim.2003.11.002","article-title":"A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies","volume":"111","author":"Letko","year":"2004","journal-title":"Clin Immunol"},{"issue":"9","key":"10.1016\/j.jaad.2020.05.161_bib88","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1001\/archderm.137.9.1181","article-title":"Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy","volume":"137","author":"Ahmed","year":"2001","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.161_bib89","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/bjd.12041","article-title":"Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid","volume":"168","author":"Munyangango","year":"2013","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.161_bib90","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ophtha.2007.04.027","article-title":"Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes","volume":"115","author":"Saw","year":"2008","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.jaad.2020.05.161_bib91","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/archderm.142.11.1457","article-title":"Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients","volume":"142","author":"Canizares","year":"2006","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib92","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.jaad.2021.02.073","article-title":"Intraepithelial autoimmune bullous dermatoses disease activity assessment and therapy","volume":"84","author":"Montagnon","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2020.05.161_bib93","doi-asserted-by":"crossref","first-page":"e87001","DOI":"10.1172\/jci.insight.87001","article-title":"Aldehyde dehydrogenase inhibition blocks mucosal fibrosis in human and mouse ocular scarring","volume":"1","author":"Ahadome","year":"2016","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.161_bib94","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaad.2013.09.041","article-title":"Development, reliability, and\u00a0validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI)","volume":"70","author":"Loh","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.161_bib95","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/jdv.13953","article-title":"The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa","volume":"31","author":"Jain","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.161_bib96","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1590\/abd1806-4841.20197198","article-title":"Assessment of the quality of life of Egyptian and Tunisian autoimmune bullous diseases' patients using an Arabic version of the autoimmune bullous disease quality of life and the treatment of autoimmune bullous disease quality of life questionnaires","volume":"94","author":"Saleh","year":"2019","journal-title":"An Bras Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2020.05.161_bib97","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s11136-015-0965-z","article-title":"Reliability of the autoimmune bullous disease quality of life (ABQOL) questionnaire in the USA","volume":"24","author":"Sebaratnam","year":"2015","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jaad.2020.05.161_bib98","series-title":"Blistering Diseases: Clinical Features, Pathogenesis, Treatment","first-page":"579","article-title":"Epidermolysis Bullosa Acquisita","author":"Prost-Squarcioni","year":"2015"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.161_bib99","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1590\/S0365-05962010000400014","article-title":"Intravenous immunoglobulin for treatment of severe acquired bullous epidermolysis refractory to conventional immunosuppressive therapy","volume":"85","author":"Mosqueira","year":"2010","journal-title":"An Bras Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.161_bib100","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1006\/clim.2001.5113","article-title":"Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab","volume":"101","author":"Egan","year":"2001","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.161_bib101","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jid.2017.08.030","article-title":"The anti-C1s antibody TNT003 prevents complement activation in the skin induced by bullous pemphigoid autoantibodies","volume":"138","author":"Kasprick","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2020.05.161_bib102","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.jid.2017.05.017","article-title":"The syk tyrosine kinase is required for skin inflammation in an in\u00a0vivo mouse model of epidermolysis bullosa acquisita","volume":"137","author":"Nemeth","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.05.161_bib103","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.jid.2016.12.021","article-title":"The leukotriene B4 and its receptor BLT1 act as critical drivers of neutrophil recruitment in murine bullous pemphigoid-like epidermolysis bullosa acquisita","volume":"137","author":"Sezin","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.05.161_bib104","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/path.4323","article-title":"Flightless I over-expression impairs skin barrier development, function and recovery following skin blistering","volume":"232","author":"Kopecki","year":"2014","journal-title":"J Pathol"},{"key":"10.1016\/j.jaad.2020.05.161_bib105","series-title":"Blistering Diseases: Clinical Features, Pathogenesis, Treatment","first-page":"589","article-title":"Management of Bullous Systemic Lupus Erythematosus","author":"Kho","year":"2015"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.161_bib106","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/RHU.0b013e318214f30c","article-title":"Rituximab in the treatment of bullous systemic lupus erythematosus","volume":"17","author":"Alsanafi","year":"2011","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.161_bib107","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1191\/0961203303lu241cr","article-title":"Bullous SLE: response to methotrexate and relationship with disease activity","volume":"12","author":"Malcangi","year":"2003","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib108","first-page":"844","article-title":"Bullous systemic lupus erythematosus responding tomycophenolate mofetil","volume":"20","author":"Hamminga","year":"2010","journal-title":"Eur J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.161_bib109","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/120347541201600110","article-title":"Mycophenolate mofetil and erythromycin for bullous lupus erythematosus of childhood","volume":"16","author":"Pehr","year":"2012","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.161_bib110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.semarthrit.2017.11.003","article-title":"Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 new cases and a literature review of 118 cases","volume":"48","author":"de Risi-Pugliese","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.161_bib111","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jaad.2014.02.036","article-title":"Anti-p200 pemphigoid","volume":"71","author":"Goletz","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.161_bib112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1346-8138.2007.00208.x","article-title":"Anti-p200 pemphigoid: a novel autoimmune subepidermal blistering disease","volume":"34","author":"Dilling","year":"2007","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.161_bib113","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-4632.2006.02969.x","article-title":"Case of concurrent epidermolysis bullosa acquisita and anti-p200 pemphigoid\u2014how to treat it?","volume":"46","author":"Pastar","year":"2007","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib114","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/j.1365-2133.2008.08483.x","article-title":"Metastatic ovarian carcinoma-associated subepidermal blistering disease with autoantibodies to both the p200 dermal antigen and the gamma 2 subunit of laminin 5 showing unusual clinical features","volume":"158","author":"Mitsuya","year":"2008","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib115","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1365-2230.2009.03731.x","article-title":"Relapse-associated autoantibodies to BP180 in a patient with anti-p200 pemphigoid","volume":"35","author":"Kasperkiewicz","year":"2010","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib116","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/bjd.12163","article-title":"A successful treatment with ustekinumab in a case of antilaminin-gamma1 pemphigoid associated with psoriasis","volume":"168","author":"Majima","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.05.161_bib117","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/014107688007300515","article-title":"Linear IgA dapsone responsive bullous dermatosis","volume":"73","author":"Wojnarowska","year":"1980","journal-title":"J R Soc Med"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib118","first-page":"849","article-title":"Case reports of linear IgA bullous dermatosis of childhood","volume":"28","author":"Ang","year":"1999","journal-title":"Ann Acad Med Singapore"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.161_bib119","first-page":"153","article-title":"Linear IgA bullous dermatosis in Tunisian children: 31 cases","volume":"56","author":"Monia","year":"2011","journal-title":"Indian J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.161_bib120","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.det.2011.06.014","article-title":"Management of linear IgA disease","volume":"29","author":"Ng","year":"2011","journal-title":"Dermatol Clin"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.161_bib121","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1046\/j.1365-2133.2000.03625.x","article-title":"Linear IgA disease: successful treatment with cyclosporin","volume":"143","author":"Young","year":"2000","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.161_bib122","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/000155502320323351","article-title":"Successful treatment of linear IgA bullous dermatosis with mycophenolate mofetil","volume":"82","author":"Glaser","year":"2002","journal-title":"Acta dermato-venereol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib123","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0190-9622(08)80651-2","article-title":"Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases","volume":"28","author":"Chaffins","year":"1993","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2020.05.161_bib124","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1001\/archderm.1984.01650430150027","article-title":"Linear IgA bullous dermatosis. Successful treatment with colchicine","volume":"120","author":"Aram","year":"1984","journal-title":"Arch Dermatol"},{"issue":"2-3","key":"10.1016\/j.jaad.2020.05.161_bib125","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s12016-009-8153-y","article-title":"High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases","volume":"38","author":"Ishii","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.161_bib126","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000279318","article-title":"Linear IgA disease: successful application of immunoadsorption and review of the literature","volume":"220","author":"Kasperkiewicz","year":"2010","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.161_bib127","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjd.15244","article-title":"Idiopathic linear IgA bullous dermatosis: prognostic factors based on\u00a0a\u00a0case series of 72 adults","volume":"177","author":"Gottlieb","year":"2017","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib128","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1365-2133.1989.tb08218.x","article-title":"Sulphamethoxypyridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid","volume":"121","author":"McFadden","year":"1989","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib129","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jaad.2010.09.776","article-title":"Dermatitis herpetiformis. Part II. Diagnosis, management, and prognosis","volume":"64","author":"Bolotin","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib130","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2133.1982.tb00520.x","article-title":"Long term follow-up of dermatitis herpetiformis with and without dietary gluten withdrawal","volume":"107","author":"Fry","year":"1982","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.161_bib131","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF02944243","article-title":"Dermatitis herpetiformis: a review of fifty-four patients","volume":"166","author":"Egan","year":"1997","journal-title":"Ir J Med Sci"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.161_bib132","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0190-9622(86)70137-0","article-title":"Long-term follow-up of dermatitis herpetiformis in children","volume":"15","author":"Ermacora","year":"1986","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib133","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1468-3083.2009.03188.x","article-title":"Guidelines for the diagnosis and treatment of dermatitis herpetiformis","volume":"23","author":"Caproni","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.161_bib134","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.iac.2012.04.007","article-title":"Management of dermatitis herpetiformis","volume":"32","author":"Cardones","year":"2012","journal-title":"Immunol Allergy Clin North Am"},{"issue":"9","key":"10.1016\/j.jaad.2020.05.161_bib135","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/jdv.15679","article-title":"Review of autoimmune blistering diseases: the pemphigoid diseases","volume":"33","author":"Daniel","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.161_bib136","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/jdv.17183","article-title":"S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"35","author":"G\u00f6r\u00f6g","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.05.161_bib137","doi-asserted-by":"crossref","first-page":"8980534","DOI":"10.1155\/2017\/8980534","article-title":"Correlation between IL36alpha and IL17 and activity of the disease in selected autoimmune blistering diseases","volume":"2017","author":"Zebrowska","year":"2017","journal-title":"Mediators Inflam"},{"key":"10.1016\/j.jaad.2020.05.161_bib138","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3389\/fimmu.2019.01290","article-title":"Dermatitis herpetiformis: novel perspectives","volume":"10","author":"Antiga","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.161_bib139","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jdermsci.2017.04.008","article-title":"Serum levels and tissue expression of interleukin-31 in dermatitis herpetiformis and bullous pemphigoid","volume":"87","author":"Bonciani","year":"2017","journal-title":"J Dermatol Sci"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221004771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221004771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T23:26:13Z","timestamp":1724801173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962221004771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":139,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0190962221004771"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.05.161","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subepithelial autoimmune bullous dermatoses disease activity assessment and therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.05.161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}